The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the BPaL treatment remains effective against highly drug-resistant strains of tuberculosis (TB) with reduced dosage and/or duration of the linezolid component of the regimen.1 Along with the maintenance of efficacy, there was a decrease in linezolid-associated side effects that accompanied the reduced dosage or duration of linezolid.1 The results from the trial, which was led by TB Alliance, a non-profit TB drug developer, were published today in the New England Journal of Medicine. Read more here.
top of page
Recent Posts
See AllPhumeza Tisile was treated for MDR-TB in 2010 and suffered severe side effects from the drug, kanamycin. Her experiences drove her to...
120
The WHO has released new guidelines for prophylactic TB treatments. Among the updates to the guidelines are adjusted dosage...
100
The TB-CAPT consortium released a new study recently that showed that the new Xpert MTB/XDR testing can provide signigificantly faster...
170
bottom of page
Comments